Competitive landscape
Drugs aimed at the same indication, from approved to preclinical.
1 drug for “EGFR Uncommon Mutations”
Phase 3 1
- FirmonertinibArriVent BioPharma, Inc.EGFR Uncommon Mutations
Drugs whose recorded indications name this term, by development stage. Indications come from registries and labels, so a drug can appear under related terms.